EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors

Etablierung eines Tiermodells für immunvermittelte unerwünschte Ereignisse durch Immun-Checkpoint-Inhibitoren

Yuan Meng iD, Yingge Lv, Meng Shen, Wenwen Yu, Yumeng Liu, Ting Liu, Gen Liu, Shiya Ma, Zhenzhen Hui, Xiubao Ren, Liang Liu

Cancer Medicine · 2024-07 · 13 (14)

DOI: 10.1002/cam4.70011 ↗

Auf einen Blick

Bei BALB/c-Mäusen mit 4T1-Tumoren führte die Gabe von PD-1- und CTLA-4-Inhibitoren zu entzündlichen Veränderungen in Organen und zu erhöhten Entzündungsmarkern. Das Modell wurde als erfolgreich etabliert beschrieben.

Fragestellung

Kann mit PD-1- und CTLA-4-Inhibitoren in BALB/c-Mäusen ein klinisch praktikables irAE-Tiermodell erzeugt werden?

Methode

BALB/c-Mäuse mit subkutanen 4T1-Tumoren; Behandlung mit PD-1- und CTLA-4-Inhibitoren alle 3 Tage über fünf Applikationszyklen; Vergleich mit Kontrolle; Beurteilung von Tumor, Gewicht, CT, H&E, ELISA und Durchflusszytometrie.

Ergebnisse

Unter PD-1- und CTLA-4-Inhibitoren sanken Tumorvolumen und Körpergewicht. Entzündungsscores waren höher, die Lungen-CT zeigte entzündliche Herde, und Ferritin, IL-6, TNF-α, IFN-γ sowie ALT waren erhöht.

Schlussfolgerung der Autor:innen

Das irAE-Modell wurde in BALB/c-Mäusen mit der Kombination aus PD-1- und CTLA-4-Inhibitoren erfolgreich etabliert und hat laut Autor:innen translationalen und praktischen Wert.

Kernaussagen

  • PD-1- und CTLA-4-Inhibitoren lösten irAE-ähnliche Veränderungen aus
  • Entzündungsmarker und Gewebeentzündung waren erhöht
  • Das Modell soll mechanistische Untersuchungen zu irAEs erleichtern

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 13.07.2024. Verfasst von Yuan Meng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Mice, Inbred BALB C, Disease Models, Animal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Natural Science Foundation, National Natural Science Foundation of China, Haihe Laboratory of Cell Ecosystem Innovation Fund.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. However, it can also cause immune‐related adverse events (irAEs). This study aimed to develop a clinically practical animal model of irAEs using BALB/c mice.

Methods

Subcutaneous tumors of mouse breast cancer 4T1 cells were generated in inbred BALB/c mice. The mice were treated with programmed death‐1 (PD‐1) and cytotoxic t‐lymphocyte antigen 4 (CTLA‐4) inhibitors once every 3 days for five consecutive administration cycles. Changes in tumor volume and body weight were recorded. Lung computed tomography (CT) scans were conducted. The liver, lungs, heart, and colon tissues of the mice were stained with hematoxylin–eosin (H&E) staining to observe inflammatory infiltration and were scored. Serum samples were collected, and enzyme‐linked immunosorbent assay (ELISA) was used to detect the levels of ferritin, glutamic‐pyruvic transaminase (ALT), tumor necrosis factor‐α (TNF‐α), interferon‐gamma (IFN‐γ), and interleukin‐6 (IL‐6). Mouse liver and lung cell suspensions were prepared, and changes in macrophages, T cells, myeloid‐derived suppressor cells (MDSCs), and regulatory (Treg) cells were detected by flow cytometry.

Results

Mice treated with PD‐1 and CTLA‐4 inhibitors showed significant reductions in tumor volume and body weight. The tissue inflammatory scores in the experimental group were significantly higher than those in the control group. Lung CT scans of mice in the experimental group showed obvious inflammatory spots. Serum levels of ferritin, IL‐6, TNF‐α, IFN‐γ, and ALT were significantly elevated in the experimental group. Flow cytometry analysis revealed a substantial increase in CD3 + T cells, Treg cells, and macrophages in the liver and lung tissues of mice in the experimental group compared with the control group, and the change trend of MDSCs was opposite.

Conclusions

The irAE‐related animal model was successfully established in BALB/c mice using a combination of PD‐1 and CTLA‐4 inhibitors through multiple administrations with clinical translational value and practical. This model offers valuable insights into irAE mechanisms for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMice, Inbred BALB CDisease Models, AnimalAnimalsMiceFemaleCTLA-4 AntigenProgrammed Cell Death 1 ReceptorCell Line, Tumor

Stichwörter der Autor:innen

animal modelcancer immunotherapyimmune checkpoint inhibitorsimmune‐related adverse events

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 ReceptorPdcd1 protein, mouse

Autor:innen und Institutionen

  • Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
  • Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

ORCID-Profile: Yuan Meng

Förderung

  • Tianjin Natural Science Foundation
  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • Natural Science Foundation of Tianjin Municipality

Zitieren

APA

Meng, Y., Lv, Y., Shen, M., Yu, W., Liu, Y., Liu, T., Liu, G., Ma, S., Hui, Z., Ren, X., & Liu, L. (2024). Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors. Cancer Medicine, 13(14). https://doi.org/10.1002/cam4.70011

Vancouver

Meng Y, Lv Y, Shen M, Yu W, Liu Y, Liu T, et al. Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors. Cancer Medicine. 2024;13(14). doi:10.1002/cam4.70011

BibTeX
@article{Meng2024,
  author = {Meng, Yuan and Lv, Yingge and Shen, Meng and Yu, Wenwen and Liu, Yumeng and Liu, Ting and Liu, Gen and Ma, Shiya and Hui, Zhenzhen and Ren, Xiubao and Liu, Liang},
  title = {Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {14},
  doi = {10.1002/cam4.70011}
}
Kostenlos starten →